You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel sanitizer/disinfectants against viral infections with long-lasting effect
SBC: CAMELLIX, LLC Topic: NIAIDAbstractNorovirus is the most common cause of acute gastroenteritis in the United States, associated annually with 19-21 million illnesses, 56,000-71,000 hospitalizations and 570-800 deaths (US CDC, Overview about Norovirus). Norovirus is one of the nonenveloped viruses that are resistant to alcohol sanitization. According to US CDC Guidelines for the Prevention and Control of Norovirus Gastroente ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated point-of-care identification of innocent Still's murmur in children
SBC: AUSCULTECH DX LLC Topic: NHLBIPROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Personalized Neural Stem Cell Therapy for Cancer
SBC: Falcon Therapeutics, Inc. Topic: NCATSPROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: 300This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia
SBC: Arrevus, Inc. Topic: NIAIDBloodstream infections (BSIs) caused by Gram-negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic-resistant nature of the pathogens. Infections caused by multi-drug resistant (MDR) bacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic options. This lack of treatment options is particularly ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease
SBC: RFPi, Inc. Topic: NHLBIABSTRACT Peripheral Arterial Disease (PAD) is a substantial healthcare burden in the US (estimated andgt; 8M) and around the world (estimated andgt; 200M). In the aging population, over 24% with age andgt; 80 years have PAD. 50% of all patients with PAD are asymptomatic, and up to 40% of the remaining patients have atypical symptoms. The conventional ankle/brachial index (cABI) ratio is establishe ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDProject Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Preventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring
SBC: Infrared Rx, Inc. Topic: NIDDKPreventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring Abstract Measurements of muscle metabolism and blood flow using near infrared spectroscopy (NIRS) have progressively increased, as has the number of companies selling NIRS-based devices. This technology represents the present and future modality for non-invasively characterizing normal and abnormal muscle physiology ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: NCIUltrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker 1 ABSTRACT Sclerotic chronic graft versus host disease (cGVHD) develops in 30 - 70% of allogenic Human Stem Cell Transplant (HCT) recipients and is associated with significant morbidity and mortality. GVHD is treated with immunosuppression, which puts patients at severe risk of infection. I ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Infant Assessment of Early Communication Risk Factors: The ISCBS (formerly ECBS)
SBC: PAUL H BROOKES PUBLISHING CO., INC. Topic: NIDCDDESCRIPTION provided by applicant Effective early intervention depends on reliable identification of risk for communication impairments as soon as possible Established infant risk factors for communication impairments include poor turn taking gestures receptive language commenting symbolic play and speech Although these risk factors can be detected by mos and reliably predict late ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health